BELLEVUE, Wash. — Viome, a precision health company specializing in RNA-based diagnostic testing and personalized nutrition, has acquired Sōlaria Biō, a developer of clinically studied synbiotics and medical foods, to expand its portfolio of targeted health products.
The acquisition combines Viome’s microbiome database with Sōlaria’s proprietary microbial biobank and AI-driven discovery platform to develop products addressing specific health conditions, including bone loss, joint health and gut barrier integrity.
Sōlaria’s lead product, Bōndia, a synbiotic medical food designed for the dietary management of bone loss, will become Viome’s first standalone product available without requiring customers to undergo Viome testing. A second product, SBD121, is under development for joint health.
“For a decade, Viome has been helping people learn what’s happening inside their bodies because we believe true personalization is the key to improving overall health and longevity,” said Naveen Jain, Founder and CEO of Viome. “Now, we’re building platforms that will help us expand to offer interventions people can act on immediately for health challenges they’re already facing.”
Bōndia has been evaluated in a randomized, placebo-controlled clinical trial. According to the company, the product reduced femoral bone loss by 84.5% in women with osteopenia and hip bone loss by up to 73.7% in women with elevated body mass index or body fat. Research supporting the product has been published in several scientific journals, including Beneficial Microbes, Osteoporosis International and the Journal of Functional Foods.
Sōlaria’s discovery platform draws on a decade of research involving microbial strains found in fruits, vegetables and fermented foods. Its biobank contains more than 5,700 bacterial and fungal isolates, while its machine-learning technology predicts microbial functions to support the development of targeted medical foods.
According to Sōlaria, the platform has reduced its product development timeline from approximately three years to 10 months.
“Sōlaria’s mission has always been to address health concerns at their earliest stages, when targeted nutrition can make the greatest difference,” said Eric Schott, Co-Founder and Chief Operating Officer of Sōlaria Biō. “By combining our plant-derived microbial discovery engine with Viome’s ability to decode the body’s unique biological signals, we can help people recognize emerging health needs sooner and respond with precision.”
The transaction follows Viome’s acquisition of Circulate Health and further expands its efforts to combine diagnostic testing with clinically studied nutritional interventions.
Viome, which is approaching its 10th anniversary, said it has analyzed more than 1 million microbiomes and generated over 140 million personalized nutritional recommendations. The company plans to use its combined biological datasets and Sōlaria’s discovery technology to develop additional condition-specific health products.
Financial terms of the acquisition were not disclosed.
